Orum Therapeutics secured about $100 million (146 billion KRW) to advance a platform that couples antibody targeting with protein‑degrading payloads—so‑called degrader‑antibody conjugates. The company reallocated resources after pausing a HER2 program because of liver toxicity signals and is prioritizing ORM‑1153, a CD123‑directed degrader for acute myeloid leukemia. Orum’s approach aims to overcome resistance mechanisms seen with traditional ADC payloads by using targeted protein degradation. The company has partnerships with Bristol Myers Squibb and Vertex and expects to enter the clinic with ORM‑1153 as early as late 2026. Investors and competitors will watch safety and differentiation closely as the degrader payload modality moves toward human testing.